There were no clinically significant safety or tolerability concerns.
The principle of AOD9604, already proven in animal studies, is to mimic the natural fat reducing properties of human growth hormone without producing any effects on blood sugar control or growth. As with previous studies there was no evidence of effects on either blood sugar control or on markers of growth.
The numbers of adverse events in the treated groups were similar to the placebo group, except at the highest (60 mg) dose. At this dose, which is in excess of the anticipated effective dose for weight reduction (see below), there were a few occasions of abdominal discomfort of various kinds, mostly shortly after dose.
MBP Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
